History
The company was founded in 1976 by Roger C. Lucas as Research and Diagnostic Systems, Inc. In 1985, it merged into Techne Corporation and became a public company. [1]
In March 2013, Charles (Chuck) Kummeth was named chief executive officer of the company. [2]
In July 2013, the company acquired Bionostics for $104 million. [3] [4]
In February 2014, the company changed its name to Bio-Techne. [5]
In April 2014, the company agreed to acquire Shanghai PrimeGene Bio-Tech Company (PrimeGene). [6] [7]
In July 2014, the company acquired Novus Biologicals for $60 million. [8] [9] [10]
In August 2014, the company acquired ProteinSimple for $300 million. [11]
In November 2014, the company agreed to acquire CyVek for $60 million plus up to an additional $135 million in earn-out payments. [12] [13] [14]
In June 2015, the company agreed to acquire Cliniqa Corporation. [15] [16]
In March 2016, the company acquired Zephyrus Biosciences. [17] [18] [19]
In July 2016, the company acquired Space Import-Export. [20]
In August 2016, company acquired Advanced Cell Diagnostics for $250 million plus an additional $75 million in possible milestone payments. [21] [22] [23]
In September 2017, the company acquired Trevigen. [24] [25]
In January 2018, the company acquired Atlanta Biologicals. [26] [27]
In June 2018, the company agreed to acquire Quad Technologies. [28] [29]
In August 2018, the company acquired Exosome Diagnostics for $250 million plus up to an additional $325 million in milestone payments. [30]
In June 2019, the company acquired B-Mogen. [31] [32]
In April 2021, the company acquired Asuragen for $215 million plus up to an additional $105 million in milestone payments. [33]
In June 2022, the business announced it would acquire Namocell Inc. [34]
In June 2023, Bio-Techne announced it would acquire Lunaphore Technologies SA, [35] the transaction was completed the following month [36]
US$1.22 billion (2025)
US$102 million (2025)